로딩 중…
지수 로딩 중…
Chong Kun Dang Pharmaceutical Corp.
185750· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩66,400+1.84%
2026-10-15
Financials
Valuation Metrics
Chong Kun Dang Pharmaceutical Corp.'s Market Cap is ₩9165B. At end of 2025 it was ₩1.1T. Ranked #319 of 2,414 in KR market (top 13%), #231 of 781 on KOSPI (top 30%), #34 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 916.50B KRW | KR#319/2,414 Sec#34/231 |
| Revenue | 1.78T KRW | KR#278/2,414 Sec#7/231 |
| Net Income | 79.57B KRW | KR#295/2,414 Sec#21/231 |
| Total Assets | 1.87T KRW | KR#312/2,414 Sec#13/231 |
| Net Assets | 1.02T KRW | KR#293/2,414 Sec#17/231 |
| Employees | 2,336 | KR#125/2,414 Sec#5/231 |
| Value | ||
| P/E | 11.52x | KR#907/2,414 Sec#48/231 |
| P/B | 0.90x | KR#1,370/2,414 Sec#83/231 |
| PEG | 0.43x | KR#680/2,414 Sec#43/231 |
| P/S | 0.51x | KR#939/2,414 Sec#41/231 |
| EV/EBITDA | 14.93x | KR#855/2,414 Sec#49/231 |
| FCF Yield | -8.03% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | 7.81% | KR#810/2,414 Sec#53/231 |
| ROA | 4.26% | KR#823/2,414 Sec#65/231 |
| Op. Margin | 4.33% | KR#1,053/2,414 Sec#76/231 |
| Revenue Growth | 7.15% | KR#1,063/2,414 Sec#102/231 |
| Earnings Growth | 26.88% | KR#667/2,414 Sec#45/231 |
| Financial Health | ||
| Debt Ratio | 83.26% | KR#1,389/2,414 Sec#161/231 |
| Total Debt | 428.32B KRW | KR#337/2,414 Sec#12/231 |
| FCF | -73.56B KRW | KR#2,104/2,414 Sec#207/231 |
| Cash | 192.29B KRW | KR#276/2,414 Sec#10/231 |
| Current Ratio | 2.04x | KR#849/2,414 Sec#97/231 |
| Net Debt/EBITDA | 3.06x | KR#911/2,414 Sec#67/231 |
| Dividend | ||
| Div. Yield | 0.75% | KR#1,181/2,414 Sec#71/231 |
| Div. Growth | -54.55% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -18.43% | KR#1,238/2,414 Sec#84/231 |
| 1M Return | 0.61% | KR#920/2,414 Sec#81/231 |
| From 52W High | -32.31% | KR#631/2,414 Sec#38/231 |
| 1Y MDD | -34.39% | KR#391/2,414 Sec#27/231 |
| Trading | ||
| Volume | 32,867 shares | KR#1,781/2,414 Sec#177/231 |
| Trading Value | 2.16B KRW | KR#738/2,414 Sec#73/231 |
| Foreign Own. | 15.62% | KR#304/2,414 Sec#18/231 |
| Per Share | ||
| EPS | 5,764 KRW | KR#190/2,414 Sec#9/231 |
| BPS | 73,777 KRW | KR#187/2,414 Sec#12/231 |
Company Info
동사는 1941년 궁본약방으로 설립되어 2013년 인적분할을 통해 의약품사업부문을 담당하는 신설회사로 재편되었으며, 유가증권시장에 재상장함. 국내 대형 제약사로서 신약 캄토벨과 듀비에정, 네스플 출시하였고 2023년 노바티스사와 HDAC6 저해제 CKD-510 기술수출 계약 체결함. 동사는 신약, 바이오의약품 연구개발과 해외시장 개척을 통해 글로벌 제약기업으로 도약하고 있음. 종근당는 2013년에 설립되었으며 서울 서대문구에 본사를 두고 있습니다.